Antimicrobial strategies: An option to treat allergy?

Biomedicine and Pharmacotherapy

Volumn 61, Issue 1, 2007, Pages 21-28

  Papadopoulos, Nikolaos G ^a   Konstantinou, George N ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Allergy; Asthma; Atopy; Infection; Viruses

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; AMANTADINE; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CHEMOKINE; CHLORPHENIRAMINE; CLARITHROMYCIN; CYTOKINE; GAMMA INTERFERON; GLUCOCORTICOID; IBUPROFEN; INFLUENZA VACCINE; INTERCELLULAR ADHESION MOLECULE 1; IPRATROPIUM BROMIDE; MACROLIDE; MONTELUKAST; NAPROXEN; OSELTAMIVIR; PALIVIZUMAB; RIBAVIRIN; RIMANTADINE; ROXITHROMYCIN; TELITHROMYCIN; TOBACCO SMOKE; ZANAMIVIR;

AIR POLLUTION; ALLERGIC ASTHMA; ARTICLE; ATOPY; BRONCHITIS; CHLAMYDOPHILA PNEUMONIAE; DISEASE EXACERBATION; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FUNCTIONAL DISEASE; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTERFERON PRODUCTION; LUNG FUNCTION; MICROORGANISM; MYCOPLASMA PNEUMONIAE; NEUROGENIC INFLAMMATION; PICORNAVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; ASTHMA; BACTERIAL INFECTIONS; CHILD; HUMANS; HYPERSENSITIVITY; PREVALENCE; VIRUS DISEASES; VIRUSES;

EID: 33846633248     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.10.004     Document Type: Article

References (131)

1. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 30 Suppl. 1 (2000) 2-5
2. Bianco A., Mazzarella G., Bresciani M., Paciocco G., and Spiteri M.A. Virus-induced asthma. Monaldi Arch Chest Dis 57 3-4 (2002) 188-190
3. Gern J.E. Rhinovirus respiratory infections and asthma. Am J Med 112 Suppl. 6A (2002) 19S-27S
4. Lemanske Jr. R.F., and Busse W.W. 6. Asthma. J Allergy Clin Immunol 111 Suppl. 2 (2003) S502-S519
5. Minor T.E., Dick E.C., DeMeo A.N., Ouellette J.J., Cohen M., and Reed C.E. Viruses as precipitants of asthmatic attacks in children. JAMA 227 3 (1974) 292-298
6. Johnston S.L., Pattemore P.K., Sanderson G., et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 154 3 Pt 1 (1996) 654-660
7. Johnston S.L., Pattemore P.K., Sanderson G., et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310 6989 (1995) 1225-1229
8. Nicholson K.G., Kent J., and Ireland D.C. Respiratory viruses and exacerbations of asthma in adults. BMJ 307 6910 (1993) 982-986
9. Rakes G.P., Arruda E., Ingram J.M., Hoover G.E., Zambrano J.C., Hayden F.G., et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 159 3 (1999) 785-790
10. Teichtahl H., Buckmaster N., and Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 112 3 (1997) 591-596
11. Tan W.C., Xiang X., Qiu D., Ng T.P., Lam S.F., and Hegele R.G. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 115 4 (2003) 272-277
12. Lemanske Jr. R.F. Is asthma an infectious disease?: Thomas A. Neff lecture. Chest 123 Suppl. 3 (2003) 385S-390S
13. Johnston S.L., and Martin R.J. Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?. Am J Respir Crit Care Med 172 9 (2005) 1078-1089
14. Papi A., Message S., Papadopoulos N., Casolari P., Ciaccia A., and Johnston N.W. Respiratory viruses and asthma. Eur Resp Monograph 23 (2003) 223-238
15. Chiu S.S., Chan K.H., Chu K.W., Kwan S.W., Guan Y., Poon L.L., et al. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis 40 12 (2005) 1721-1729
16. Williams J.V., Crowe Jr. J.E., Enriquez R., et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 192 7 (2005) 1149-1153
17. Arnold J.C., Singh K.K., Spector S.A., and Sawyer M.H. Human bocavirus: prevalence and clinical spectrum at a children's hospital. Clin Infect Dis 43 3 (2006) 283-288
18. Choi E.H., Lee H.J., Kim S.J., et al. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin Infect Dis 43 5 (2006) 585-592
19. Ma X., Endo R., Ishiguro N., Ebihara T., Ishiko H., Ariga T., et al. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol 44 3 (2006) 1132-1134
20. Macek V., Sorli J., Kopriva S., and Marin J. Persistent adenoviral infection and chronic airway obstruction in children. Am J Respir Crit Care Med 150 1 (1994) 7-10
21. Miller R. Viral infections of the respiratory tract. In: Thurlbeck W. (Ed). Pathology of the lung (1988), Thieme Medical Publishers, New York 147-179
22. Wilson N.M. Virus infections, wheeze and asthma. Paediatr Respir Rev 4 3 (2003) 184-192
23. Matsuse T., Hayashi S., Kuwano K., Keunecke H., Jefferies W.A., and Hogg J.C. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 146 1 (1992) 177-184
24. Gern J.E. Viral respiratory infection and the link to asthma. Pediatr Infect Dis J 23 Suppl. 1 (2004) S78-S86
25. Monto A.S. Studies of the community and family: acute respiratory illness and infection. Epidemiol Rev 16 2 (1994) 351-373
26. Crighton E.J., Mamdani M.M., and Upshur R.E. A population based time series analysis of asthma hospitalisations in Ontario, Canada: 1988 to 2000. BMC Health Serv Res 1 1 (2001) 7
27. Blaisdell C.J., Weiss S.R., Kimes D.S., Levine E.R., Myers M., Timmins S., et al. Using seasonal variations in asthma hospitalizations in children to predict hospitalization frequency. J Asthma 39 7 (2002) 567-575
28. Johnston N.W., Johnston S.L., Duncan J.M., et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 115 1 (2005) 132-138
29. Johnston N.W., Johnston S.L., Norman G.R., Dai J., and Sears M.R. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 117 3 (2006) 557-562
30. Xirasagar S., Lin H.C., and Liu T.C. Seasonality in pediatric asthma admissions: the role of climate and environmental factors. Eur J Pediatr 165 11 (2006) 747-752
31. Harper G.J. The influence of environment on the survival of airborne virus particles in the laboratory. Arch Gesamte Virusforsch 13 (1963) 64-71
32. Pirtle E.C., and Beran G.W. Virus survival in the environment. Rev Sci Tech 10 3 (1991) 733-748
33. Xatzipsalti M., Kyrana S., Tsolia M., Psarras S., Bossios A., Laza-Stanca V., et al. Rhinovirus viremia in children with respiratory infections. Am J Respir Crit Care Med 172 8 (2005) 1037-1040
34. Kusel M.M., de Klerk N.H., Holt P.G., Kebadze T., Johnston S.L., and Sly P.D. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J 25 8 (2006) 680-686
35. van Benten I., Koopman L., Niesters B., et al. Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Allergy Immunol 14 5 (2003) 363-370
36. Simpson J.L., Moric I., Wark P.A., Johnston S.L., and Gibson P.G. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques. J Clin Virol 26 3 (2003) 339-346
37. Sattar S.A., Jacobsen H., Springthorpe V.S., Cusack T.M., and Rubino J.R. Chemical disinfection to interrupt transfer of rhinovirus type 14 from environmental surfaces to hands. Appl Environ Microbiol 59 5 (1993) 1579-1585
38. Grunberg K., Sharon R.F., Hiltermann T.J., Brahim J.J., Dick E.C., Sterk P.J., et al. Experimental rhinovirus 16 infection increases intercellular adhesion molecule-1 expression in bronchial epithelium of asthmatics regardless of inhaled steroid treatment. Clin Exp Allergy 30 7 (2000) 1015-1023
39. Grunberg K., Smits H.H., Timmers M.C., de Klerk E.P., Dolhain R.J., Dick E.C., et al. Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects. Am J Respir Crit Care Med 156 2 Pt 1 (1997) 609-616
40. Laza-Stanca V., Stanciu L.A., Message S.D., Edwards M.R., Gern J.E., and Johnston S.L. Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production. J Virol 80 16 (2006) 8248-8258
41. Papi A., and Johnston S.L. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. J Biol Chem 274 14 (1999) 9707-9720
42. Papi A., and Johnston S.L. Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors. J Biol Chem 274 42 (1999) 30041-30051
43. Gern J.E., Calhoun W., Swenson C., Shen G., and Busse W.W. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 155 6 (1997) 1872-1876
44. Xepapadaki P., Papadopoulos N.G., Bossios A., Manoussakis E., Manousakas T., and Saxoni-Papageorgiou P. Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. J Allergy Clin Immunol 116 2 (2005) 299-304
45. Ando M., Shima M., Adachi M., and Tsunetoshi Y. The role of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and regulated on activation, normal T-cell expressed and secreted (RANTES) in the relationship between air pollution and asthma among children. Arch Environ Health 56 3 (2001) 227-233
46. Grunberg K., Timmers M.C., Smits H.H., de Klerk E.P., Dick E.C., Spaan W.J., et al. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy 27 1 (1997) 36-45
47. Cheung D., Dick E.C., Timmers M.C., de Klerk E.P., Spaan W.J., and Sterk P.J. Rhinovirus inhalation causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects in vivo. Am J Respir Crit Care Med 152 5 Pt 1 (1995) 1490-1496
48. Grunberg K., Timmers M.C., de Klerk E.P., Dick E.C., and Sterk P.J. Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma. Am J Respir Crit Care Med 160 4 (1999) 1375-1380
49. Papi A., Stanciu L.A., Papadopoulos N.G., Teran L.M., Holgate S.T., and Johnston S.L. Rhinovirus infection induces major histocompatibility complex class I and costimulatory molecule upregulation on respiratory epithelial cells. J Infect Dis 181 5 (2000) 1780-1784
50. Gern J.E., Vrtis R., Grindle K.A., Swenson C., and Busse W.W. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med 162 6 (2000) 2226-2231
51. Chung K.F., and Barnes P.J. Cytokines in asthma. Thorax 54 9 (1999) 825-857
52. Wark P.A., Johnston S.L., Bucchieri F., Powell R., Puddicombe S., Laza-Stanca V., et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201 6 (2005) 937-947
53. Bossios A., Xatzipsalti M., Manoussakis E., Psarros F., Saxoni-Papageorgiou P., and Papadopoulos N.G. Expression of costimulatory molecules in peripheral blood mononuclear cells of atopic asthmatic children during virus-induced asthma exacerbations. Int Arch Allergy Immunol 134 3 (2004) 223-226
54. Fraenkel D.J., Bardin P.G., Sanderson G., Lampe F., Johnston S.L., and Holgate S.T. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 151 3 Pt 1 (1995) 879-886
55. Hu C., Wedde-Beer K., Auais A., Rodriguez M.M., and Piedimonte G. Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol 283 2 (2002) L494-L502
56. Joos G.F., De Swert K.O., Schelfhout V., and Pauwels R.A. The role of neural inflammation in asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci 992 (2003) 218-230
57. Tortorolo L., Langer A., Polidori G., Vento G., Stampachiacchere B., Aloe L., et al. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 172 2 (2005) 233-237
58. Papadopoulos N.G., Stanciu L.A., Papi A., Holgate S.T., and Johnston S.L. A defective type 1 response to rhinovirus in atopic asthma. Thorax 57 4 (2002) 328-332
59. Bufe A., Gehlhar K., Grage-Griebenow E., and Ernst M. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol 127 1 (2002) 82-88
60. Gehlhar K., Bilitewski C., Reinitz-Rademacher K., Rohde G., and Bufe A. Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy 36 3 (2006) 331-337
61. Tang M., Kemp A., and Varigos G. IL-4 and interferon-gamma production in children with atopic disease. Clin Exp Immunol 92 1 (1993) 120-124
62. Brooks G.D., Buchta K.A., Swenson C.A., Gern J.E., and Busse W.W. Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. Am J Respir Crit Care Med 168 9 (2003) 1091-1094
63. Stephens R., Randolph D.A., Huang G., Holtzman M.J., and Chaplin D.D. Antigen-nonspecific recruitment of Th2 cells to the lung as a mechanism for viral infection-induced allergic asthma. J Immunol 169 10 (2002) 5458-5467
64. Chauhan A.J., Inskip H.M., Linaker C.H., Smith S., Schreiber J., Johnston S.L., et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet 361 9373 (2003) 1939-1944
65. Sears M.R. Epidemiology of childhood asthma. Lancet 350 9083 (1997) 1015-1020
66. Abramson M.J., Marks G.B., and Pattemore P.K. Are non-allergenic environmental factors important in asthma?. Med J Aust 163 10 (1995) 542-545
67. Chauhan A.J., and Johnston S.L. Air pollution and infection in respiratory illness. Br Med Bull 68 (2003) 95-112
68. Frampton M.W., Boscia J., Roberts Jr. N.J., et al. Nitrogen dioxide exposure: effects on airway and blood cells. Am J Physiol Lung Cell Mol Physiol 282 1 (2002) L155-L165
69. Spannhake E.W., Reddy S.P., Jacoby D.B., Yu X.Y., Saatian B., and Tian J. Synergism between rhinovirus infection and oxidant pollutant exposure enhances airway epithelial cell cytokine production. Environ Health Perspect 110 7 (2002) 665-670
70. Murray C.S., Poletti G., Kebadze T., Morris J., Woodcock A., Johnston S.L., et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 61 5 (2006) 376-382
71. Green R.M., Custovic A., Sanderson G., Hunter J., Johnston S.L., and Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 324 7340 (2002) 763
72. Sotir M., Yeatts K., and Shy C. Presence of asthma risk factors and environmental exposures related to upper respiratory infection-triggered wheezing in middle school-age children. Environ Health Perspect 111 4 (2003) 657-662
73. Black P.N., Blasi F., Jenkins C.R., et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 164 4 (2001) 536-541
74. Kraft M., Cassell G.H., Pak J., and Martin R.J. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 121 6 (2002) 1782-1788
75. Rubin B.K., and Henke M.O. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125 Suppl. 2 (2004) 70S-78S
76. Tamaoki J., Kadota J., and Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117 Suppl. 9A (2004) 5S-11S
77. Wark P.A., Johnston S.L., Simpson J.L., Hensley M.J., and Gibson P.G. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J 20 4 (2002) 834-840
78. Hahn D.L. Chlamydia pneumoniae infection and asthma. Lancet 339 8802 (1992) 1173-1174
79. Byrne G.I., and Ojcius D.M. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat Rev Microbiol 2 10 (2004) 802-808
80. Nagy A., Kozma G.T., Keszei M., Treszl A., Falus A., and Szalai C. The development of asthma in children infected with Chlamydia pneumoniae is dependent on the modifying effect of mannose-binding lectin. J Allergy Clin Immunol 112 4 (2003) 729-734
81. Johnston S.L., Blasi F., Black P.N., Martin R.J., Farrell D.J., and Nieman R.B. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354 15 (2006) 1589-1600
82. Plotkin S.A. Vaccines, vaccination, and vaccinology. J Infect Dis 187 9 (2003) 1349-1359
83. Sunnegardh J. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease-who should receive it?. Acta Paediatr 95 4 (2006) 388-390
84. Littel-van den Hurk S.V., Mapletoft J.W., Arsic N., and Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol (2006) [Epub ahead of print]
85. Bright R.A., Medina M.J., Xu X., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 9492 (2005) 1175-1181
86. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 8 (2006) 891-894
87. Hayden F.G. Antiviral resistance in influenza viruses-implications for management and pandemic response. N Engl J Med 354 8 (2006) 785-788
88. Hayden F., Klimov A., Tashiro M., et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 10 8 (2005) 873-877
89. Russell R.J., Haire L.F., Stevens D.J., et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 7107 (2006) 45-49
90. Fleming D.M., Crovari P., Wahn U., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25 10 (2006) 860-869
91. Halloran M.E., Longini Jr. I.M., Gaglani M.J., Piedra P.A., Chu H., Herschler G.B., et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 158 4 (2003) 305-311
92. Zangwill K.M., and Belshe R.B. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 23 3 (2004) 189-197
93. Gaglani M.J., Piedra P.A., Herschler G.B., et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158 1 (2004) 65-73
94. Nicholson K.G., Nguyen-Van-Tam J.S., Ahmed A.H., et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 351 9099 (1998) 326-331
95. Bueving H.J., Bernsen R.M., de Jongste J.C., et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 169 4 (2004) 488-493
96. Kotenko S.V., Gallagher G., Baurin V.V., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 1 (2003) 69-77
97. Scott G.M., Phillpotts R.J., Wallace J., Gauci C.L., Greiner J., and Tyrrell D.A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet 2 8291 (1982) 186-188
98. Samo T.C., Greenberg S.B., Couch R.B., Quarles J., Johnson P.E., Hook S., et al. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 148 3 (1983) 535-542
99. Hayden F.G., and Gwaltney Jr. J.M. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis 148 3 (1983) 543-550
100. Douglas R.M., Albrecht J.K., Miles H.B., Moore B.W., Read R., Worswick D.A., et al. Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection. J Infect Dis 151 4 (1985) 731-736
101. Monto A.S., Shope T.C., Schwartz S.A., and Albrecht J.K. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis 154 1 (1986) 128-133
102. Higgins P.G., Al-Nakib W., Willman J., and Tyrrell D.A. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Res 6 2 (1986) 153-159
103. Sperber S.J., Levine P.A., Innes D.J., Mills S.E., and Hayden F.G. Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults. J Infect Dis 158 1 (1988) 166-175
104. Sperber S.J., Levine P.A., Sorrentino J.V., Riker D.K., and Hayden F.G. Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds. J Infect Dis 160 4 (1989) 700-705
105. Contoli M., Message S.D., Laza-Stanca V., et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12 9 (2006) 1023-1026
106. Sperber S.J., and Hayden F.G. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. J Interferon Res 9 3 (1989) 285-293
107. Gwaltney Jr. J.M. Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 166 4 (1992) 776-782
108. Papi A., Papadopoulos N.G., Degitz K., Holgate S.T., and Johnston S.L. Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells. J Allergy Clin Immunol 105 2 Pt 1 (2000) 318-326
109. Grunberg K., Sharon R.F., Sont J.K., et al. Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Respir Crit Care Med 164 10 Pt 1 (2001) 1816-1822
110. Farr B.M., Gwaltney Jr. J.M., Hendley J.O., et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 162 5 (1990) 1173-1177
111. Harrison T.W., Oborne J., Newton S., and Tattersfield A.E. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363 9405 (2004) 271-275
112. FitzGerald J.M., Becker A., Sears M.R., Mink S., Chung K., and Lee J. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59 7 (2004) 550-556
113. Edwards M.R., Johnson M.W., and Johnston S.L. Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol 34 5 (2006) 616-624
114. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 7246 (2000) 1368-1373
115. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 8 Pt 1 (2001) 1392-1397
116. van Schaik S.M., Tristram D.A., Nagpal I.S., Hintz K.M., Welliver II R.C., and Welliver R.C. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 103 4 (1999) 630-636
117. Volovitz B., Welliver R.C., De Castro G., Krystofik D.A., and Ogra P.L. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 24 4 (1988) 504-507
118. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., and Edwards T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158 11 (1998) 1213-1220
119. Kemp J.P., Dockhorn R.J., Shapiro G.G., Nguyen H.H., Reiss T.F., Seidenberg B.C., et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133 3 (1998) 424-428
120. Knorr B., Matz J., Bernstein J.A., Nguyen H., Seidenberg B.C., Reiss T.F., et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279 15 (1998) 1181-1186
121. Bisgaard H., Zielen S., Garcia-Garcia M.L., Johnston S.L., Gilles L., Menten J., et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171 4 (2005) 315-322
122. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 167 3 (2003) 379-383
123. Papi A., Papadopoulos N.G., Stanciu L.A., Degitz K., Holgate S.T., and Johnston S.L. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 108 2 (2001) 221-228
124. Psarras S., Caramori G., Contoli M., Papadopoulos N., and Papi A. Oxidants in asthma and in chronic obstructive pulmonary disease (COPD). Curr Pharm Des 11 16 (2005) 2053-2062
125. Hammerschlag M.R. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J Antimicrob Chemother 45 Suppl. 1 (2000) 35-39
126. Chu H.W., Honour J.M., Rawlinson C.A., Harbeck R.J., and Martin R.J. Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 71 3 (2003) 1520-1526
127. Hammerschlag M.R., Roblin P.M., and Bebear C.M. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother 48 Suppl. T1 (2001) 25-31
128. Zhanel G.G., Dueck M., Hoban D.J., Vercaigne L.M., Embil J.M., Gin A.S., et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61 4 (2001) 443-498
129. Richeldi L., Ferrara G., Fabbri L.M., Lasserson T.J., and Gibson P.G. Macrolides for chronic asthma. Cochrane Database Syst Rev 3 (2005) CD002997
130. Richeldi L., Ferrara G., Fabbri L.M., Lasserson T.J., and Gibson P.G. Macrolides for chronic asthma. Cochrane Database Syst Rev 4 (2005) CD002997
131. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 20 (1997) 1405-1411